Drug details
Afinitor Disperz (everolimus tablets)
type of Antineoplastics mTOr Kinase Inhibitors
Afinitor Disperz (everolimus tablets for oral suspension) is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic; adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib; adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery; adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected; and for adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures.
This drug may have the following side effects:
- shortness of breath,
- nausea,
- headache,
- vomiting,
- diarrhea,
- weakness,
- cough,
- itching,
- constipation,
- joint pain,
- fever,
- weight loss,
- dry mouth,
- insomnia,
- nosebleed,
- rash,
- back pain,
- fatigue,
- abdominal pain,
- changes in taste,
- swelling of extremities,
- high blood sugar (hyperglycemia),
- decreased appetite,
- swelling and sores inside the mouth,
- infections (such as respiratory tract infection),
- pain in extremities,
- pneumonitis,
- hair loss, and
- hot flushes
The following drugs are related to Afinitor Disperz, either as a replacement or used together:
- Krazati (adagrasib tablets)
- Rybrevant (amivantamab-vmjw for injection)
- Azedra (iobenguane i 131 injection)
- Welireg (belzutifan tablets)
- Zirabev (bevacizumab-bvzr injection)
- Libtayo (cemiplimab-rwlc injection)
- Cosela (trilaciclib for injection)
- Vizimpro (dacomitinib)
- Elzonris (tagraxofusp-erzs injection)
- Fotivda (tivozanib capsules)
- Fyarro (sirolimus protein-bound particles for injectable suspension)
- Herzuma (trastuzumab-pkrb for injection)
- Jaypirca (pirtobrutinib tablets)
- Vitrakvi (larotrectinib capsules)
- Lumakras (sotorasib tablets)
- Margenza (margetuximab-cmkb injection, for intravenous use)
- Poteligeo (mogamulizumab-kpkc injection)
- Udenyca (pegfilgrastim-cbqv injection)
- Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf injection)
- Tepmetko (tepotinib tablets)